Table 3 Unadjusted and adjusted hazard ratios of the impact of MMR immunophenotype on overall survival in I-type tumors, PB-type tumors, and the entire cohort
Intestinal type | Pancreatobiliary type | All | |||||||
|---|---|---|---|---|---|---|---|---|---|
n (events) | Unadjusted | Adjusted | n (events) | Unadjusted | Adjusted | n (events) | Unadjusted | Adjusted | |
HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
Age | |||||||||
Continuous | 63 (39) | 1.01 (0.98–1.05) | – | 109 (98) | 0.99 (0.97–1.02) | – | 172 (137) | 1.01 (0.99–1.03) | – |
Gender | |||||||||
Female | 35 (17) | 1.00 | 1.00 | 51 (45) | 1.00 | – | 86 (62) | 1.00 | – |
34 (16)* | |||||||||
Male | 28 (22) | 2.01 (1.05–3.84) | 1.60 (0.79–3.24) | 58 (53) | 1.15 (0.77–1.71) | 86 (75) | 1.40 (1.00–1.97) | ||
27 (21)* | |||||||||
Tumor origin | |||||||||
Intestinal | – | – | – | – | 63 (39) | 1.00 | 1.00 | ||
61 (37)* | |||||||||
Pancreatobiliary type | – | – | – | – | 109 (98) | 2.54 (1.73–3.73) | 1.61 (1.01–2.55) | ||
108 (98)* | |||||||||
Tumor size | |||||||||
Continuous | 63 (39) | 1.00 (0.98–1.02) | – | 109 (98) | 1.04 (1.02–1.06) | 1.02 (1.00–1.04) | 172 (137) | 1.02 (1.00–1.03) | 1.01 (0.99–2.55) |
108 (98)* | 169 (135)* | ||||||||
T-stage | |||||||||
T1–T2 | 16 (8) | 1.00 | – | 15 (10) | 1.00 | 1.00 | 31 (18) | 1.00 | 1.00 |
14 (10)* | 28 (16)* | ||||||||
T3–T4 | 47 (31) | 1.72 (0.79–3.74) | 94 (88) | 2.47 (1.28–4.77) | 1.06 (0.50–2.27) | 141 (119) | 2.34 (1.42–3.86) | 1.21 (0.66–2.21) | |
94 (88)* | 141 (119)* | ||||||||
N-stage | |||||||||
N0 | 35 (19) | 1.00 | – | 32 (25) | 1.00 | 1.00 | 67 (44) | 1.00 | 1.00 |
31 (25)* | 64 (42)* | ||||||||
N1–2 | 28 (20) | 1.56 (0.83–2.94) | 77 (73) | 2.23 (1.41–3.54) | 2.06 (1.16–3.65) | 105 (93) | 2.19 (1.52–3.16) | 1.34 (0.88–2.05) | |
77 (73)* | 105 (93)* | ||||||||
Differentiation grade | |||||||||
Well-moderate | 31 (17) | 1.00 | – | 42 (32) | 1.00 | 1.00 | 73 (49) | 1.00 | 1.00 |
41 (32)* | 71 (48)* | ||||||||
Poor | 32 (22) | 1.70 (0.90–3.21) | 67 (66) | 2.63 (1.70–4.09) | 2.05 (1.24–3.39) | 99 (88) | 2.24 (1.57–3.18) | 1.65 (1.09–2.48) | |
67 (66)* | 98 (87)* | ||||||||
Involved margins, status | |||||||||
R0 | 18 (5) | 1.00 | 1.00 | 7 (5) | 1.00 | – | 25 (10) | 1.00 | 1.00 |
17 (4)* | 23 (9)* | ||||||||
R1 and Rx | 45 (34) | 3.30 (1.29–8.46) | 2.89 (0.94–8.85) | 102 (93) | 2.42 (0.98–6.00) | 147 (127) | 3.57 (1.87–6.83) | 2.23 (1.10–4.51) | |
44 (33)* | 146 (126)* | ||||||||
Lymphatic growth | |||||||||
Absent | 28 (10) | 1.00 | 1.00 | 35 (27) | 1.00 | 1.00 | 63 (37) | 1.00 | 1.00 |
28 (10)* | 34 (27)* | 62 (37)* | |||||||
Present | 35 (29) | 3.94 (1.90–8.18) | 1.77 (0.77–4.09) | 74 (71) | 1.78 (1.13–2.79) | 1.09 (0.65–1.83) | 109 (100) | 2.54 (1.73–3.73) | 1.33 (0.85–2.07) |
33 (27)* | 74 (71)* | 107 (98)* | |||||||
Vascular growth | |||||||||
Absent | 58 (34) | 1.00 | 1.00 | 73 (62) | 1.00 | 1.00 | 131 (96) | 1.00 | 1.00 |
56 (32)* | 72 (62)* | 128 (94)* | |||||||
Present | 5 (5) | 6.68 (2.40–18.62) | 4.69 (1.48–14.84) | 36 (36) | 2.47 (1.61–3.80) | 2.20 (1.38–3.52) | 41 (41) | 3.49 (2.37–5.15) | 2.18 (1.43–3.34) |
5 (5)* | 36 (36)* | 41 (41)* | |||||||
Perineural growth | |||||||||
Absent | 43 (21) | 1.00 | 1.00 | 25 (19) | 1.00 | 1.00 | 68 (40) | 1.00 | 1.00 |
42 (20)* | 24 (19)* | 66 (39)* | |||||||
Present | 20 (18) | 2.81 (1.48–5.35) | 1.36 (0.57–3.21) | 84 (79) | 1.96 (1.18–3.25) | 0.88 (0.48–1.61) | 104 (97) | 2.96 (2.02–4.43) | 1.06 (0.66–1.71) |
19 (17)* | 84 (79)* | 103 (96)* | |||||||
Growth in peripancreatic fat | |||||||||
Absent | 42 (20) | 1.00 | 1.00 | 25 (20) | 1.00 | 1.00 | 67 (40) | 1.00 | 1.00 |
40 (18)* | 24 (20)* | 64 (38)* | |||||||
Present | 21 (19) | 3.65 (1.86–7.16) | 1.78 (0.73–4.33) | 84 (78) | 1.75 (1.06–2.88) | 0.99 (0.56–1.77) | 105 (97) | 3.00 (2.03–4.43) | 1.37 (0.85–2.22) |
21 (19)* | 84 (78)* | 105 (97)* | |||||||
Adjuvant treatment | |||||||||
None | 45 (30) | 1.00 | – | 50 (44) | 1.00 | – | 95 (74) | 1.00 | – |
Any | 18 (9) | 0.69 (0.33–1.47) | 59 (54) | 0.96 (0.64–1.42) | 77 (63) | 1.09 (0.78–1–53) | |||
MMR | |||||||||
pMMR | 49 (34) | 1.00 | 1.00 | 101 (93) | 1.00 | 1.00 | 150 (127) | 1.00 | 1.00 |
49 (34)* | 101 (93)* | 150 (127)* | |||||||
dMMR | 12 (3) | 0.20 (0.06–0.68) | 0.36 (0.09–1.42) | 7 (5) | 0.57 (0.23–1.42) | 1.24 (0.46–3.37) | 19 (8) | 0.28 (0.13–0.57) | 0.52 (0.23–1.19) |
12 (3)* | 7 (5)* | 19 (8)* | |||||||